A Phase I Study of Subutinib Maleate Capsules on Toleration and Pharmacokinetics
1. purpose: to explore the maximum tolerated dose, dose-limiting toxicity of oral Subutinib Maleate capsules and rational dosage regimen for phase Ⅱ study
2. Experimental Design： A phase Ⅰ study of single-center
3. Test drug: Subutinib Maleate capsules
4. Sample size≥20
Solid Tumor
DRUG: Subutinib Maleate capsules
Dose-limiting toxicity， maximum tolerated dose., 2 months
Pharmacokinetics, Subutinib Maleate pharmacokinetic parameters , include AUC, Cmax, Tmax, and t1/2, 2 months|Pharmacodynamics, The response of Subutinib Maleate on tumor., 2 months
The primary objective of this study is to explore the maximum tolerated dose, dose-limiting toxicity of oral Subutinib Maleate capsules and rational dosage regimen for phase Ⅱ study, to investigate the pharmacokinetics of single and multiple oral doses of Subutinib Maleate capsules.